InMed Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
InMed Pharmaceuticals' CEO is Eric Adams, appointed in Jun 2016, has a tenure of 8.42 years. total yearly compensation is $415.40K, comprised of 70.8% salary and 29.2% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $11.45K. The average tenure of the management team and the board of directors is 4 years and 2.5 years respectively.
Belangrijke informatie
Eric Adams
Algemeen directeur
US$415.4k
Totale compensatie
| Percentage CEO-salaris | 70.8% |
| Dienstverband CEO | 8.4yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 4yrs |
| Gemiddelde ambtstermijn bestuur | 2.5yrs |
Recente managementupdates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | US$415k | US$294k | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | n/a | n/a | -US$6m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | US$368k | US$278k | -US$8m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | n/a | n/a | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | US$468k | US$363k | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | n/a | n/a | -US$14m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | US$735k | US$328k | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | n/a | n/a | -US$7m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | US$424k | US$287k | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$11m |
| Sep 30 2019 | n/a | n/a | -US$10m |
| Jun 30 2019 | US$1m | US$287k | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$9m |
| Dec 31 2018 | n/a | n/a | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$7m |
| Jun 30 2018 | US$2m | US$240k | -US$6m |
Compensatie versus markt: Eric's total compensation ($USD415.40K) is below average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: Eric's compensation has increased whilst the company is unprofitable.
CEO
Eric Adams (60 yo)
8.4yrs
Tenure
US$415,400
Compensatie
Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.4yrs | US$415.40k | 0.33% $ 11.5k | |
| CFO & Corporate Secretary | less than a year | US$274.85k | 0% $ 0 | |
| Chief Operating Officer | 2.3yrs | US$349.20k | 0.00016% $ 5.6 | |
| Senior Vice President of Clinical & Regulatory Affairs | 8.1yrs | US$313.60k | 0% $ 0 | |
| Senior Vice President of Preclinical Research & Development | 6.7yrs | US$322.50k | 0.00038% $ 13.2 | |
| Co-Founder | no data | US$142.43k | geen gegevens | |
| VP of Accounting & Controller | 4.8yrs | geen gegevens | geen gegevens | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Vice President of Sales & Marketing | 2.8yrs | geen gegevens | geen gegevens | |
| Senior VP & GM of BayMedica | 3.1yrs | geen gegevens | geen gegevens | |
| Senior Consultant of Medical Affairs | no data | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren management: INM's management team is considered experienced (4 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 8.4yrs | US$415.40k | 0.33% $ 11.5k | |
| Independent Chair of the Board | 8.2yrs | US$77.50k | 0.29% $ 10.0k | |
| Independent Director | 2.5yrs | US$52.50k | 0% $ 0 | |
| Member of the Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 2.8yrs | US$52.50k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$52.50k | 0% $ 0 | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens |
2.5yrs
Gemiddelde duur
58.5yo
Gemiddelde leeftijd
Ervaren bestuur: INM's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.